Literature DB >> 27303184

Recurrent Classical Type of Kaposi's Sarcoma Treated by Interferon-alpha.

Min Ju Kang1, Tae Yoon Kim1.   

Abstract

Kaposi's sarcoma (KS) is a lympho-angioproliferative disease, with four variants; one of which is classical KS (CKS). Classical KS is clinically characterized by single or multiple pea-sized bluish-red macules on the distal portions of the lower extremities. A 60-year-old man presented with an asymptomatic, solitary patch on the left sole. He had been successfully treated for the classical type of Kaposi sarcoma on the right sole with interferon-alpha 3 years before. The patient was treated with six million units of interferon-alpha three times per week for 6 months. The lesion showed complete resolution and there has been no report of recurrence for 1 year after treatment.

Entities:  

Keywords:  Interferon-alpha; Kaposi's sarcoma

Year:  2008        PMID： 27303184      PMCID： PMC4903971          DOI： 10.5021/ad.2008.20.3.162

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


  9 in total

Review 1.  Therapeutic strategies for epidemic Kaposi's sarcoma.

Authors:  M Aldenhoven; N P Barlo; C J G Sanders
Journal:  Int J STD AIDS       Date:  2006-09       Impact factor: 1.359

2.  New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma.

Authors:  João P Tardivo; Auro Del Giglio; Luis H Paschoal; Mauricio S Baptista
Journal:  Photomed Laser Surg       Date:  2006-08       Impact factor: 2.796

Review 3.  Epidemic Kaposi's sarcoma.

Authors:  M Cianfrocca; J H Roenn
Journal:  Oncology (Williston Park)       Date:  1998-09       Impact factor: 2.990

4.  Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.

Authors:  M Corbellino; G Bestetti; C Scalamogna; S Calattini; M Galazzi; L Meroni; D Manganaro; M Fasan; M Moroni; M Galli; C Parravicini
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

5.  Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study.

Authors:  Susan E Krown; Ping Li; Jamie H Von Roenn; Josephine Paredes; Jie Huang; Marcia A Testa
Journal:  J Interferon Cytokine Res       Date:  2002-03       Impact factor: 2.607

6.  Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet.

Authors:  Mario Luppi; Patrizia Barozzi; Valeria Rasini; Giovanni Riva; Alessandro Re; Giuseppe Rossi; Gisella Setti; Silvio Sandrini; Fabio Facchetti; Giuseppe Torelli
Journal:  Transplantation       Date:  2002-07-15       Impact factor: 4.939

7.  Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient.

Authors:  Osama Gheith; Adel Bakr; Ehab Wafa; Ashraf Fouda; Amgad El Agroudy; Ayman Refaie; Ahmed Donia; Alaa Sabry; Mohamed Sobh; Ahmed Shokeir; Mohamed Ghoneim
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

8.  Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b.

Authors:  C S Costa da Cunha; C Lebbe; M Rybojad; F Agbalika; F Ferchal; C Rabian; M D Vignon-Pennamen; F Calvo; P Morel
Journal:  Arch Dermatol       Date:  1996-03

9.  Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions.

Authors:  M Caccialanza; S Marca; R Piccinno; G Eulisse
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-03       Impact factor: 6.166
  9 in total
  1 in total

1.  Treatment of Disseminated Classic Type of Kaposi's Sarcoma with Paclitaxel.

Authors:  Soo Yeon Kim; Dae Hoon Kim; Hyo Jin Lee; Young Joon Seo; Jeung Hoon Lee; Young Lee
Journal:  Ann Dermatol       Date:  2011-11-03       Impact factor: 1.444
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.